Singapore
IP Director/ in-house IP counsel/ Registered Singapore Patent Attorney in the biopharma industry. My IP career spans roles as a former patent examiner (IPOS), private practice (Spruson & Ferguson), healthcare open innovation manager, and currently as an in-house lP leader. With a PhD, LLB, and Graduate Cert in IP Law, I am dedicated to combining deep scientific understanding with legal and commercial insights to create robust IP strategies for cutting-edge technologies and life-changing therapies. Recognised by the IAM Strategy 300 as one of the World's Leading IP Strategists. Let's connect if you're interested in IP strategy, biotech innovation and partnerships.
Heads the IP team at Chugai Singapore - Identify & develop IP opportunities for technology & drug R&D projects in SG & Japan - Devise global IP Strategies for R&D projects in close partnership with R&D, BD & Product development teams - Patent drafting, filing, prosecution and portfolio management - Perform FTO, IP landscape & competitive intelligence for strategic actionable insights. - Handle opposition and appeal proceedings, and support IP litigation activities for Chugai Group - Conduct due diligence for licensing opportunities - Review licensing, research collaboration, MTA & other agreements - Conduct in-house IP trainings to researchers - Part of the team to accelerate digital transformation of Chugai global IP group Chugai Pharmabody is a subsidiary of Chugai Pharmaceutical, Japan leading biopharma and a member of the Roche group
Provided technology scouting & evaluation services. Matched companies with strategic open innovation partners in the Biotech, Medtech, Healthcare industries. Appointed by SPRING/Enterprise Singapore to conduct due diligence for healthcare investments.
Performed prior art search, technology and patentability assessment on hundreds of patent applications (SG and PCT applications), particularly in the areas of biotech, pharma & medtech. Consistently among the most productive examiners in the Biotech Cluster. Part of team of 3, spearhead the Learning & Development (L&D) program for ~100 patent examiners from ideation, planning to execution Appointed to provide tech-specific trainings to fellow examiners on biotech practices Selected to represent IPOS to attend: - Best Practice in Life Sciences S&E sharing session, IPOS-USPTO Examiner Exchange Programme 2015 - IPOS-USPTO Senior Patent Examiner Training 2017 - IPOS-USPTO Benchmarking program 2017 (L&D)
Invited for short-term visit for a collaborative research on de-novo designed peptides for tumor-activated liposome/nanoparticle platform (SK Lim et al. Sci Rep 2016) Host: Prof. Daniel Aili
- Biosensors R&D for endotoxin and cancer biomarkers detection (SK Lim et al. Anal Chem. 2015) - Self-assembled lipid/polymer vesicles (Front Cover: RSC Soft Matter SK Lim et al. 2017; Patented US10710044B2, licensed to a biotech firm) • Author/Co-author of >7 research articles and 2 patent fillings